CryoPort Inc (CYRX)
NASDAQ:CYRX
Want to see CYRX full AI Analyst Report?
Top Page
CryoPort
(NASDAQ:CYRX)
Select Model
Select Model
Rating:61Neutral
Price Target:
$11.00
▲(19.44% Upside)
Action:ReiteratedDate:05/05/26
The score is held back primarily by weak cash generation and still-negative operating profitability despite improved reported earnings and a stronger balance sheet. Offsetting this, the technical setup is constructive and the latest earnings call was notably positive with accelerating growth and raised revenue guidance, while valuation appears supportive on a low P/E.
Positive Factors
Integrated services and deep CGT pipeline
CryoPort's breadth—766 supported clinical trials including 91 in Phase III and 21 commercial therapies—creates a durable addressable base for recurring logistics, consumables and services. A deep, maturing pipeline increases probability of commercial conversions and cross‑sell of higher‑margin offerings over multiple years.
Negative Factors
Negative operating and free cash flow
Persistent negative operating and free cash flow indicates the business still consumes cash despite reported net income improvement. This creates ongoing funding needs, raises execution risk for multi‑quarter projects, and constrains reinvestment without external financing until operating cash flow turns sustainably positive.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated services and deep CGT pipeline
CryoPort's breadth—766 supported clinical trials including 91 in Phase III and 21 commercial therapies—creates a durable addressable base for recurring logistics, consumables and services. A deep, maturing pipeline increases probability of commercial conversions and cross‑sell of higher‑margin offerings over multiple years.
Read all positive factors
CryoPort (CYRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$519.55M
Dividend YieldN/A
Average Volume (3M)690.07K
Price to Earnings (P/E)6.8
Beta (1Y)1.19
Revenue Growth-22.86%
EPS Growth62.52%
CountryUS
Employees1,090
SectorIndustrials
Sector Strength72
IndustryIntegrated Freight & Logistics
Share Statistics
EPS (TTM)1.38
Shares Outstanding50,197,906
10 Day Avg. Volume860,552
30 Day Avg. Volume690,069
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.96
Price to Sales (P/S)2.73
P/FCF Ratio-19.21
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue2.67
Enterprise Value/Gross Profit5.66
Enterprise Value/Ebitda-61.44
Forecast
1Y Price Target
$12.75Price Target Upside38.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$191.79M
CryoPort Business Overview & Revenue Model
Company Description
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platfor...
How the Company Makes Money
CryoPort primarily makes money by providing end-to-end, temperature-controlled logistics services for biopharmaceutical customers, with revenue largely generated on a per-shipment and/or contracted-services basis. Key revenue streams include: (1) ...
CryoPort Key Performance Indicators (KPIs)
CryoPort Earnings Call Summary
Earnings Call Date:May 04, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call presented a predominantly positive operational and financial picture: strong 16% revenue growth, double-digit expansion across services and products, record clinical trial support, product innovation (Fusion 800), and a $2.2M improvement in adjusted EBITDA. Management raised full-year revenue guidance and expects positive adjusted EBITDA in H2 2026. Key near-term cautions include a conservative guide raise despite a beat, the company not yet at positive adjusted EBITDA, product-margin mix variability, and multi-quarter ramps for IntegraCell and new facilities that limit 2026 contribution. Overall the positives (top-line growth, pipeline depth, milestones, margin improvement initiatives, and operational expansions) materially outweigh the identified lowlights.Positive Updates
Top-Line Growth
Revenue of $47.8 million in Q1 2026, up 16% year over year, representing a strong start to the year and prompting an upward revision to full-year revenue guidance of $192 million to $196 million.
Negative Updates
Cautious Guiding Despite Beat
Although Q1 beat consensus by $3 million, management raised full-year guidance only modestly ($1 million), citing macroeconomic uncertainty and taking a conservative stance early in the year.
Read all updates
Q1-2026 Updates
Positive
Negative
Top-Line Growth
Revenue of $47.8 million in Q1 2026, up 16% year over year, representing a strong start to the year and prompting an upward revision to full-year revenue guidance of $192 million to $196 million.
Read all positive updates
Company Guidance
Management raised full‑year 2026 revenue guidance to $192–$196 million (continuing operations) after a strong Q1 start with revenue of $47.8 million, up 16% year‑over‑year; Q1 commercial cell & gene therapy revenue was $9.1M (up 26% YoY), clinical trial revenue was $12.9M (up 18% YoY), Life Sciences Services revenue rose 18% with biostorage/bioservices up 21%, and Life Sciences Products grew 15%; the company now supports 766 global clinical trials (net +55 YoY) including 91 Phase III programs, supports 21 commercial therapies with up to eight potential new approvals this year (five with PDUFA dates), and reported a $2.2M year‑over‑year improvement in adjusted EBITDA from continuing operations (Q1 adjusted EBITDA ~‑$0.6M), reiterating an expectation to reach positive adjusted EBITDA in the second half of 2026 and noting they will reassess guidance quarterly.CryoPort Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
66
Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 176.18M | 233.25M | 237.28M | 222.61M | 222.61M |
| Gross Profit | 83.05M | 99.33M | 103.87M | 96.58M | 96.58M |
| EBITDA | -11.65M | -66.36M | -6.19M | -248.91M | -248.91M |
| Net Income | 70.30M | -99.59M | -37.33M | -275.53M | -275.53M |
Balance Sheet | |||||
| Total Assets | 764.99M | 703.49M | 957.74M | 1.04B | 1.11B |
| Cash, Cash Equivalents and Short-Term Investments | 411.21M | 261.75M | 456.75M | 523.32M | 628.80M |
| Total Debt | 230.72M | 250.70M | 416.00M | 435.91M | 427.06M |
| Total Liabilities | 262.35M | 301.59M | 468.72M | 482.91M | 471.14M |
| Stockholders Equity | 502.64M | 401.90M | 489.02M | 555.84M | 641.83M |
Cash Flow | |||||
| Free Cash Flow | -25.02M | -33.58M | -45.66M | -26.05M | -16.88M |
| Operating Cash Flow | -8.58M | -16.32M | -757.00K | -1.85M | 8.13M |
| Investing Cash Flow | 250.32M | 176.81M | 36.05M | -59.68M | -469.25M |
| Financing Cash Flow | -21.07M | -161.53M | -23.80M | -39.17M | 564.34M |
CryoPort Technical Analysis
Positive
9.21
Price Trends
8.59
Positive
9.23
Positive
9.01
Positive
Market Momentum
0.47
Negative
74.60
Negative
90.77
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYRX, the sentiment is Positive. The current price of 9.21 is above the 20-day moving average (MA) of 8.97, above the 50-day MA of 8.59, and above the 200-day MA of 9.01, indicating a bullish trend. The MACD of 0.47 indicates Negative momentum. The RSI at 74.60 is Negative, neither overbought nor oversold. The STOCH value of 90.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYRX.
CryoPort Risk Analysis
CryoPort disclosed 33 risk factors in its most recent earnings report. CryoPort reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CryoPort Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $18.78B | 13.19 | 14.02% | 2.98% | 11.11% | 4.25% | |
71 Outperform | $23.46B | 35.63 | 17.30% | 0.89% | 0.58% | 17.20% | |
68 Neutral | $93.93B | 22.26 | 15.76% | 1.94% | 4.69% | 17.55% | |
64 Neutral | $25.28B | 56.34 | 17.81% | ― | 3.63% | -11.81% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
61 Neutral | $519.55M | 6.84 | 17.12% | ― | -22.86% | 62.52% | |
50 Neutral | $6.47B | 190.29 | 1.09% | ― | 12.55% | -72.29% |
* Industrials Sector Average
CYRX
CryoPort
10.21
4.42
76.34%
XPO
XPO
199.95
90.66
82.95%
FDX
FedEx
357.80
145.53
68.56%
JBHT
JB Hunt
238.34
106.19
80.35%
ZTO
ZTO Express
24.98
6.65
36.25%
GXO
GXO Logistics
46.27
8.94
23.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.